Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.20
-0.25 (-0.63%)
May 8, 2026, 1:58 PM CST

TPEX:7427 Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1.211.694.850.540.63
Revenue Growth (YoY)
-28.49%-65.26%798.15%-14.29%-
Cost of Revenue
2.390.670.040.080.35
Gross Profit
-1.181.024.810.460.28
Selling, General & Admin
26.3528.5717.519.3717.7
Research & Development
72.0285.0953.1349.8919.11
Operating Expenses
98.36113.6670.6369.2636.8
Operating Income
-99.54-112.65-65.82-68.79-36.52
Interest Expense
-0.1-0.13-0.09--
Interest & Investment Income
8.027.795.330.940.52
Currency Exchange Gain (Loss)
-0.06-0.540.330.13
Other Non Operating Income (Expenses)
-5.85000.390.02
EBT Excluding Unusual Items
-97.47-104.92-61.12-67.13-35.86
Gain (Loss) on Sale of Assets
--0.12--
Pretax Income
-97.47-104.92-61-67.13-35.86
Net Income
-97.47-104.92-61-67.13-35.86
Net Income to Common
-97.47-104.92-61-67.13-35.86
Shares Outstanding (Basic)
4341362421
Shares Outstanding (Diluted)
4341362421
Shares Change (YoY)
4.63%13.60%50.23%14.54%33.09%
EPS (Basic)
-2.26-2.55-1.68-2.78-1.70
EPS (Diluted)
-2.26-2.55-1.68-2.78-1.70
Free Cash Flow
-87.84-78.96-57.92-77.21-33.96
Free Cash Flow Per Share
-2.04-1.92-1.60-3.20-1.61
Gross Margin
-98.26%60.24%99.11%85.93%44.92%
Operating Margin
-8260.91%-6685.28%-1357.11%-12739.07%-5796.98%
Profit Margin
-8089.05%-6226.94%-1257.67%-12431.85%-5691.59%
Free Cash Flow Margin
-7289.46%-4685.82%-1194.21%-14298.70%-5389.68%
EBITDA
-91.86-108.62-63.22-67.03-35.08
D&A For EBITDA
7.684.032.61.761.44
EBIT
-99.54-112.65-65.82-68.79-36.52
Source: S&P Global Market Intelligence. Standard template. Financial Sources.